These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 36402940)

  • 41. Incidence of corneal adverse events in patients with multiple myeloma and their clinical and economic impact: A real-world retrospective cohort study.
    Wang F; Sansbury L; Ferrante S; Maiese EM; Willson J; Chen CC; Nunna S; Sun K; Kleinman DM
    J Med Econ; 2022; 25(1):182-192. PubMed ID: 35023807
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-world treatment patterns, healthcare resource utilisation and costs in patients with systemic lupus erythematosus treated with belimumab: a retrospective analysis of claims data in the USA.
    Bell CF; Priest J; Stott-Miller M; Kan H; Amelio J; Song X; Limone B; Noxon V; Costenbader KH
    Lupus Sci Med; 2020; 7(1):e000357. PubMed ID: 32341790
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Health care utilization patterns and costs for patients with hidradenitis suppurativa.
    Kirby JS; Miller JJ; Adams DR; Leslie D
    JAMA Dermatol; 2014 Sep; 150(9):937-44. PubMed ID: 24908260
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Incidence rates of comorbidities among patients with psoriasis in the United States.
    Feldman SR; Hur P; Zhao Y; Tian H; Wei Z; Wang X; Herrera V
    Dermatol Online J; 2018 Oct; 24(10):. PubMed ID: 30677809
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Prevalent Comorbidome at the Onset of Psoriasis Diagnosis.
    Buja A; Miatton A; Cozzolino C; Brazzale AR; Lo Bue R; Mercuri SR; Proft FN; Kridin K; Cohen AD; Damiani G
    Dermatol Ther (Heidelb); 2023 Sep; 13(9):2093-2105. PubMed ID: 37542678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical characteristics and health-care resource utilization in patients with generalized pustular psoriasis using real-world evidence from the Japanese Medical Data Center database.
    Okubo Y; Kotowsky N; Gao R; Saito K; Morita A
    J Dermatol; 2021 Nov; 48(11):1675-1687. PubMed ID: 34390028
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Economic Burden of Eosinophilic Gastritis and Eosinophilic Enteritis in the United States.
    Woolley M; Cook EE; Mu F; Betts KA; Billmyer E; Yim E; Chen J; Wu EQ
    Adv Ther; 2022 Aug; 39(8):3547-3559. PubMed ID: 35689161
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Healthcare Utilization and Costs Among US Adolescents With Alopecia Areata.
    Ray M; Swallow E; Gandhi K; Carley C; Sikirica V; Wang T; Done N; Signorovitch J; Mostaghimi A
    J Health Econ Outcomes Res; 2022; 9(2):11-18. PubMed ID: 35975139
    [No Abstract]   [Full Text] [Related]  

  • 49. Treatment patterns, healthcare resource utilization, and costs in patients with moderate-to-severe psoriasis treated with systemic therapy in Japan: A retrospective claims database study.
    Tada Y; Kim H; Spanopoulos D; Habiro K; Tsuritani K; Yamada Y; Mandal A; Zhong Y; Hikichi Y
    J Dermatol; 2022 Nov; 49(11):1106-1117. PubMed ID: 35946343
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retrospective Analysis of Disease Severity, Health Care Resource Utilization, and Costs Among Patients Initiating Belimumab for the Treatment of Systemic Lupus Erythematosus.
    Lokhandwala T; Coutinho AD; Bell CF
    Clin Ther; 2021 Aug; 43(8):1320-1335. PubMed ID: 34243966
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey.
    Lebwohl M; Langley RG; Paul C; Puíg L; Reich K; van de Kerkhof P; Wu HL; Richter S; Jardon S; Gisondi P
    Dermatol Ther (Heidelb); 2022 Jan; 12(1):61-78. PubMed ID: 34704231
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Hospital Healthcare Resource Utilization and Associated Hospital Costs of Patients With Lupus Nephritis in China: A National Administrative Claim Database Study.
    He X; Zhu X; Tang Z; Gairy K; Juliao P; Wu Z; Han S
    Value Health Reg Issues; 2024 Jun; 43():101001. PubMed ID: 38850589
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical Costs Associated with High/Moderate/Low Likelihood of Adult Growth Hormone Deficiency: A Healthcare Claims Database Analysis.
    Yuen KCJ; Blevins LS; Clemmons DR; Faurby M; Hoffman AR; Kelepouris N; Kerr JM; Tarp JM; Fleseriu M
    Clinicoecon Outcomes Res; 2024; 16():133-147. PubMed ID: 38476578
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Healthcare Costs and Resource Utilization Associated with the Use of Empagliflozin Versus Other Antihyperglycemic Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease: A Real-World Retrospective Cohort Analysis.
    Raju A; Pimple P; Stafkey-Mailey D; Farrelly E; Shetty S
    Diabetes Ther; 2022 Jan; 13(1):25-42. PubMed ID: 34727356
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Burden of chronic urticaria relative to psoriasis in five European countries.
    Balp MM; Khalil S; Tian H; Gabriel S; Vietri J; Zuberbier T
    J Eur Acad Dermatol Venereol; 2018 Feb; 32(2):282-290. PubMed ID: 28898460
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comorbidity Burden and Treatment Patterns of Psoriasis in Vietnam: Real-World Data from the EXPAND Study.
    Nguyen HT; Vu AT; Pham NTU; Tran TNA; Pham NN; Bui HTT; Pham TT; Dinh VTT; Bui YT; Vu TTP
    Dermatol Ther (Heidelb); 2023 Dec; 13(12):3193-3208. PubMed ID: 37978119
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Real-world medication use and economic outcomes in incident systemic lupus erythematosus patients in the United States.
    Kariburyo F; Xie L; Sah J; Li N; Lofland JH
    J Med Econ; 2020 Jan; 23(1):1-9. PubMed ID: 31589081
    [No Abstract]   [Full Text] [Related]  

  • 58. Real-world treatment patterns and healthcare costs in patients with psoriasis taking systemic oral or biologic therapies.
    Thai S; Zhuo J; Zhong Y; Xia Q; Chen X; Bao Y; Dhanda D; Priya L; Wu JJ
    J Dermatolog Treat; 2023 Dec; 34(1):2176708. PubMed ID: 36794863
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical and Economic Burden of Chronic Heart Failure and Reduced Ejection Fraction Following a Worsening Heart Failure Event.
    Butler J; Djatche LM; Sawhney B; Chakladar S; Yang L; Brady JE; Yang M
    Adv Ther; 2020 Sep; 37(9):4015-4032. PubMed ID: 32761552
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Economic Burden of Recurrence Among Resected Medicare Patients With Early Stage NSCLC.
    Lee JM; Wang R; Johnson A; Ogale S; Kent M; Lee JS
    JTO Clin Res Rep; 2023 Apr; 4(4):100487. PubMed ID: 37007869
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.